Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A

CONCLUSIONS: Hemostatic efficacy was maintained, and safety remained unchanged from previous years.PMID:38614387 | DOI:10.1016/j.jtha.2024.04.001

Source: Thrombosis and Haemostasis - April 13, 2024 Category: Hematology Authors: Bella Madan Margareth C Ozelo Priyanka Raheja Emily Symington Doris V Quon Andrew D Leavitt Steven W Pipe Gillian Lowe Gili Kenet Mark T Reding Jane Mason Michael Wang Annette von Drygalski Robert Klamroth Susan Shapiro Herv é Chambost Amy L Dunn Johanne Source Type: research